Georgian health authorities have temporarily suspended the registration of roughly 3,000 pharmaceutical products as part of updated regulatory compliance checks. The affected pharmaceuticals primarily originate from former Soviet countries, with additional batches imported from India, Bangladesh, and select European producers.
Stricter Quality Requirements
The administrative decision stems from enforced Good Manufacturing Practice (GMP quality standards) across the national healthcare sector. Under the updated framework, foreign drug manufacturers are required to submit European quality certification for active pharmaceutical ingredients used in their formulations.
Regulatory bodies indicated that medications lacking verified documentation would remain suspended until full compliance is demonstrated by suppliers.
Industry Response and Market Impacts
Responding to the decision, the Pharmaceutical Companies Association clarified that several international manufacturers missed administrative document deadlines rather than failing technical laboratory tests. Industry representatives rejected assertions that the regulatory shift was intended to deliberately clear lower-cost medicines from pharmacy shelves.
Despite official clarifications, market analysts and healthcare observers note that the temporary suspension could temporarily restrict access to cheaper alternative drugs across local pharmacies while certification reviews continue.
